Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia
about
Role of aqueous extract of Azadirachta indica leaves in an experimental model of Alzheimer's disease in ratsCholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's diseaseA double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease.Arecoline induced disruption of expression and localization of the tight junctional protein ZO-1 is dependent on the HER 2 expression in human endometrial Ishikawa cells.Allosteric Modulation of Muscarinic Acetylcholine Receptors.The noradrenergic system in Alzheimer and multi-infarct dementiasNeurotransmitter replacement therapy in Alzheimer's disease.Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.Therapeutic approaches to age-associated neurocognitive disordersEvaluation of arecoline hydrobromide toxicity after a 14-day repeated oral administration in Wistar rats.A novel series of non-quaternary oxadiazoles acting as full agonists at muscarinic receptors.Hormesis and medicine.Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth.Critical review of clinical trials in senile dementia--II.Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors.Electrophysiological estimation of the actions of acetylcholinesterase inhibitors on acetylcholine receptor and cholinesterase in physically isolated Aplysia neurones.Synthesis of Novel 3-Aryl-N-Methyl-1,2,5,6-Tetrahydropyridine Derivatives by Suzuki coupling: As Acetyl Cholinesterase Inhibitors.The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro.Alzheimer's disease: recent advances and future prospects.Pharmacokinetics of physostigmine in man following a single application of a transdermal system.
P2860
Q30453444-331CAAF9-B28C-44A0-B2DC-103EF2B5044BQ33619760-E3DED84C-47A6-4CBF-AB71-6921FA53A8F3Q33621285-A38B8A1C-DC23-4268-814B-A9B51611EED0Q33626062-185EB929-38CB-473B-BC0C-10C15318954AQ33664703-441CF919-1652-4496-B6F9-BA44E4FAD5DCQ33755706-8530D729-7166-453F-9E7D-DFB2E83FFC4FQ33921314-4A338566-9B1E-442E-97F9-39FBD2002972Q35066849-14058DB3-9F4C-449E-9176-0FC14D1F6F08Q35236387-1A0458FC-4580-4C56-B8DC-7C1E3638E702Q35448074-A09E87FB-ED1A-423A-B925-6BD7ADF504BBQ35888346-9A28773C-5601-45F4-B464-BC05CA8CE682Q37142421-F9EC5CD8-0072-4591-AEEF-760510300FACQ38729991-74BA0254-3A04-481F-B496-38FE6E18A6AFQ39173624-109A95E6-514B-4526-94EB-EEF0B2A0E050Q41846364-6480AEAA-3A65-49C4-B8EB-253DFA83C521Q41868084-4DF3C271-4025-4CC4-8935-0BA3D230A1A1Q41906294-16F9D09B-869B-4017-9645-A397CA42B94EQ42847596-C47AA27A-5B0E-4D82-8CD8-C606EF1A1524Q42852240-8AD64A95-6A70-4345-8347-3C00DB7A8A04Q43201827-993F8804-D452-49C3-8D69-B0E301623D02
P2860
Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia
description
1981 nî lūn-bûn
@nan
1981 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1981 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
name
Physostigmine and arecoline: e ...... n Alzheimer presenile dementia
@ast
Physostigmine and arecoline: e ...... n Alzheimer presenile dementia
@en
Physostigmine and arecoline: e ...... n Alzheimer presenile dementia
@nl
type
label
Physostigmine and arecoline: e ...... n Alzheimer presenile dementia
@ast
Physostigmine and arecoline: e ...... n Alzheimer presenile dementia
@en
Physostigmine and arecoline: e ...... n Alzheimer presenile dementia
@nl
prefLabel
Physostigmine and arecoline: e ...... n Alzheimer presenile dementia
@ast
Physostigmine and arecoline: e ...... n Alzheimer presenile dementia
@en
Physostigmine and arecoline: e ...... n Alzheimer presenile dementia
@nl
P2093
P1476
Physostigmine and arecoline: e ...... n Alzheimer presenile dementia
@en
P2093
J E Christie
J Ferguson
P407
P577
1981-01-01T00:00:00Z